An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Center Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1/PD-L1 Containing Therapy (HUDSON)
HUDSON: Study of Multiple Treatments in Patients with Non-Small Cell Lung Cancer (NSCLC)
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAR6575
U.S. Govt. ID: NCT03334617
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: This is an open-label, Phase II study in patients with metastatic non-small cell lung cancer (NSCLC) whose cancer has gotten worse on an anti-programmed cell death-1/anti-programmed cell death ligand 1 (anti-PD-1/PD-L1) containing therapy. This study consists of a number of treatment cohorts to test the efficacy, safety, and tolerability of multiple treatment arms. There is currently no established therapy for patients who have received immune checkpoint inhibitors and platinum-doublet therapies, and new treatments are urgently needed.
This study is closed
Catherine Shu, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with metastatic or recurrent non-small cell lung cancer? Yes No
Has your disease worsened following treatment with chemotherapy and an anti-PD-1/PD-L1 therapy (ex. Opdivo or Keytruda)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator